文献速递炎症性肠病

AGA技术综述:中重度溃疡性结肠炎的管理

AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.
PubMed 文献 · Gastroenterology · 2020-01-13

该技术综述基于GRADE框架,针对中重度UC门诊患者和急性重症UC住院患者,系统评价了不同药物诱导和维持缓解的疗效、生物制剂单药与联合免疫调节剂的比较、升阶梯与降阶梯策略、5-氨基水杨酸续用与否,以及住院患者激素抵抗后的药物选择、激素和英夫利西单抗剂量、辅助抗生素作用等7个重点问题。

要点

  • 中重度UC患者面临高结肠切除、住院、激素依赖和严重感染风险。
  • 门诊治疗常需免疫调节剂和/或生物制剂,单用或联合使用。
  • 急性重症UC住院患者危及生命的并发症和急诊手术风险尤其高。

核心结论

  • 中重度UC的优化管理常需使用免疫调节剂和/或生物制剂以降低结肠切除、住院、激素依赖和严重感染风险。
  • 不同药物治疗的比较疗效和安全性证据有限,导致临床实践差异大,AGA优先制定相关临床指南。

研究设计与样本

  • 本技术综述按照GRADE框架完成,以支持AGA临床指南的制定。
  • 聚焦问题涉及成人中重度UC门诊患者和急性重症UC住院患者。

关键数值与推荐

  • 门诊患者重点问题包括不同药物诱导和维持缓解的总体及比较疗效(有无TNF-α拮抗剂暴露史)、生物制剂单药与联合免疫调节剂的比较疗效和安全性、降阶梯与升阶梯治疗的比较疗效、以及正在接受免疫调节剂和/或生物制剂治疗的中重度UC患者继续与停用5-氨基水杨酸的作用。
  • 住院患者重点问题包括激素抵抗的急性重症UC患者药物干预降低结肠切除风险的总体及比较疗效、静脉激素和英夫利西单抗的最佳剂量方案、以及无确认感染时辅助抗生素的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A subset of patients with ulcerative colitis (UC) present with, or progress to, moderate to severe disease activity. These patients are at high risk for colectomy, hospitalization, corticosteroid dependence, and serious infections. The risk of life-threatening complications and emergency colectomy is particularly high among those patients hospitalized with acute severe ulcerative colitis. Optimal management of outpatients or inpatients with moderate to severe UC often requires the use of immunomodulator and/or biologic therapies, including thiopurines, methotrexate, cyclosporine, tacrolimus, TNF-α antagonists, vedolizumab, tofacitnib, or ustekinumab, either as monotherapy or in combination (with immunomodulators), to mitigate these risks. Decisions about optimal drug therapy in moderate to severe UC are complex, with limited guidance on comparative efficacy and safety of different treatments, leading to considerable practice variability. Therefore, the American Gastroenterological Association prioritized development of clinical guidelines on this topic. To inform the clinical guidelines, this technical review was completed in accordance with the Grading of Recommendations Assessment, Development and Evaluation framework. Focused questions in adult outpatients with moderate to severe UC included: (1) overall and comparative efficacy of different medications for induction and maintenance of remission in patients with or without prior exposure to TNF-α antagonists, (2) comparative efficacy and safety of biologic monotherapy vs combination therapy with immunomodulators, (3) comparative efficacy of top-down (upfront use of biologics and/or immunomodulator therapy) vs step-up therapy (acceleration to biologic and/or immunomodulator therapy only after failure of 5-aminosalicylates, and (4) role of continuing vs stopping 5-aminosalicylates in patients being treated with immunomodulator and/or biologic therapy for moderate to severe UC. Focused questions in adults hospitalized with acute severe ulcerative colitis included: (5) overall and comparative efficacy of pharmacologic interventions for inpatients refractory to corticosteroids, in reducing risk of colectomy, (6) optimal dosing regimens for intravenous corticosteroids and infliximab in these patients, and (7) role of adjunctive antibiotics in the absence of confirmed infections.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Singh S, Allegretti JR, Siddique SM, et al. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020. PMID: 31945351. doi:10.1053/j.gastro.2020.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。